Educational Objectives

 Discuss and implement the National Cholesterol Education Program
 Adult Treatment Panel (NCEP ATP) III Guidelines.

 Discuss lipoprotein metabolism and its role in the pathogenesis
 of atherosclerosis.

 Recognize the role of drug therapy in the management of
 dyslipidemias.

 Recognize side effects of drug therapy including rhabdomyolysis.

 Identify the essential features of the therapeutic lifestyle changes
 approach to reducing the risk for coronary heart disease (CHD).

 Manage dyslipidemias according to patient profiles.

 Designate various disorders as CHD Risk Equivalents.

 Recognize the metabolic syndrome and its associated risk factors.

 Classify diabetes as a CHD Risk Equivalent.

 Manage non-lipid risk factors for dyslipidemias including hypertension,
 obesity, and cigarette smoking.

Subject Content

 National Cholesterol Education Program Adult Treatment Panel
 (NCEP ATP) III Guidelines including:
 Low density lipoprotein cholesterol.
 Global risk assessment.
 Other lipid risk factors.
 Non-lipid risk factors including hypertension, cigarette smoking,
 obesity and diet.

 Treatment of diabetes as a risk equivalent.

 Lipoprotein metabolism and pathogenesis of atherosclerosis.

 Therapeutic lifestyle changes approach to reduce risk.

 Drug therapy for dyslipidemias.

 Statins.

 Fibrates.

 Niacin.

 Bile acid sequestrants.

 New drugs.

 New drugs in development.

 Side effects of drug therapy.

 Genetic disorders.

Back to Lipidology Introduction